Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

JAMA - 1 Jan 2000

Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole J J, Coakley D

Abstract excerpt

CONTEXT: Adefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration. OBJECTIVE: To determine if adefovir confers antiretroviral or immunologic benefit when added to stable antiretroviral therapy. DESIGN: Multicenter, 24-week, randomized, double-blind, placebo-controlled study. Enrollment was conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Organophosphonates
Share to Adenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-HIV Agents

Share to CD4 Lymphocyte Count

Share to Double-Blind Method

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to Zidovudine

Source

Identifiers

PMID: 10612317
DOI: 10.1001/jama.282.24.2305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.PMID 10612317Read ↗

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.Semantic proximity Read ↗

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Semantic proximity Read ↗

Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.Semantic proximity Read ↗

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Semantic proximity Read ↗

Tenofovir disoproxil fumarate.Semantic proximity Read ↗

Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.Semantic proximity Read ↗

Treatment of patients with chronic hepatitis B with adefovir dipivoxil.Semantic proximity Read ↗

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.Semantic proximity Read ↗

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.